La vendita allo scoperto per Jaguar Health dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Jaguar Health. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Jaguar Health (NASDAQ:JAGX) Azioni, Report sulle vendite allo scoperto

Jaguar Health

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Jaguar Health Inc

631,922 Shares of Common Stock Issuable Upon the Conversion of Outstanding Notes
622,584 Shares of Common Stock Issuable Upon the Exercise of Outstanding Common Warrants
37,376 Shares of Common Stock Issuable Upon the Exercise of Outstanding Placement Agent Warrants
This prospectus relates to the resale of up to 1,291,882 shares of Jaguar Health, Inc. (the "Company," "we," "our" or "us") voting common stock, par value $0.0001 per share (the "Common Stock"), by the Selling Stockholders listed in this prospectus (the "Selling Stockholders"). The shares of Common Stock registered for resale pursuant to this prospectus consist of (i)&nbsp;631,922 shares of Common Stock (the "Conversion Shares") issuable upon the conversion of the 6% convertible promissory notes (the "Notes"), (ii)&nbsp;622,584 shares of Common Stock (the "Common Warrant Shares") issuable upon the exercise of common warrants (the "Common Warrants"), and (iii)&nbsp;37,376 shares of Common Stock (the "Placement Agent Warrant Shares," and together with the Common Warrant Shares, the "Warrant Shares") issuable upon the exercise of certain warrants issued to our placement agent (the "Placement Agent Warrants" and together with the Common Warrants, the "Warrants"). The Notes and Warrants were issued to the Selling Stockholders in a private placement offering (the "Private Placement") that closed on March&nbsp;31, 2025.
For additional information about the Private Placement, see "Private Placement."
The Notes are immediately convertible, at each holder's option, in part or in full, into Conversion Shares at a conversion price of $5.535 per share for holders who are not an officer, director, employee or consultant of the Company (collectively, a "Company Insider"), and $5.555 per share for holders who are Company Insiders. The Common Warrants have an exercise price of $5.41 per share for holders who are not Company Insiders, and $5.43 per share for holders who are Company Insiders, and are exercisable immediately upon issuance and will expire on the earlier of (i)&nbsp;five years from the date of issuance, (ii)&nbsp;the consummation of a fundamental transaction and (iii)&nbsp;the consummation of a liquidation event. The Placement Agent Warrants have substantially the same terms as the Warrants, except that the Placement Agent Warrants have an exercise price of $6.9188 per share.

News

Offerings

JAGX

Jaguar Health Registers 1.29M Shares Of Common Stock For Resale From Private Placement That Closed On March 31, 2025, Including Shares Issuable From Convertible Notes, Common Warrants, And Placement Agent Warrants

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 45.1% to $4.15 during Wednesday's after-market session. The company's market cap stands at $3.4 million. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares increased by 15.64% to $0.2. The company's market cap stands at $5.1 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock rose 13.18% to $0.6. The market value of their outstanding shares is at $9.2 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock increased by 13.16% to $0.28. The company's market cap stands at $1.4 million. </li>
<li>Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) shares rose 11.43% to $7.7. The market value of their outstanding shares is at $569.8 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) shares rose 10.08% to $1.31. The market value of their outstanding shares is at $21.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares declined by 7.5% to $2.21 during Wednesday's after-market session. The company's market cap stands at $10.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares fell 7.31% to $0.19. The market value of their outstanding shares is at $4.8 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock declined by 6.95% to $11.39. The market value of their outstanding shares is at $7.6 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares declined by 6.94% to $0.31. The market value of their outstanding shares is at $19.2 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 6.46% to $0.29. The company's market cap stands at $11.5 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) stock fell 6.26% to $5.55. The market value of their outstanding shares is at $201.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIMD

AUNA

BDMD

GCTK

IRIX

NAOV

PASG

PCSA

PLRZ

12 Health Care Stocks Moving In Wednesday's After-Market Session

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the <a href="https://pr.report/9xgt">Annual ELITE PED-GI Congress</a>; Click <a href="https://pr.report/9xgu">here</a> to register
There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay
This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) <a href="https://pr.report/9xgv">PRIME</a> program for expediated and assisted regulatory approval in the EU as well as FDA's <a href="https://pr.report/9xgw">Breakthrough Therapies</a> program for expedited regulatory approval in the US
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 30, 2025 / <a href="https://pr.report/9xgb">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/9xgd">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/9xge">Napo Therapeutics</a> today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.

Jaguar Health Announces Initial Proof-Of-Concept Results Showing That Novel Liquid Formulation Of Crofelemer Reduced Required TPN And/Or Supplementary Intravenous Fluids In MVID And SBS-IF Patients

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click <a href="https://viavid.webcasts.com/starthere.jsp?ei=1718118&amp;tp_key=02fe2f82c4">here</a> to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the <a href="https://www.elite-pedgi.com/">Annual ELITE PED-GI Congress</a> by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study

Biotech

Events

General

Jaguar Health To Present Initial Results From Proof-of-Concept Study of Crofelemer For Rare Diseases Microvillus Inclusion Disease And Short Bowel Syndrome With Intestinal Failure

<h3>Gainers</h3>
<ul>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock increased by 61.0% to $12.98 during Friday's regular session. The company's market cap stands at $8.7 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 42.96% to $2.26. The company's market cap stands at $31.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares rose 23.66% to $0.28. The market value of their outstanding shares is at $3.9 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock rose 15.48% to $7.68. The market value of their outstanding shares is at $45.5 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 15.06% to $3.97. The company's market cap stands at $2.1 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 14.45% to $0.53. The market value of their outstanding shares is at $2.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares declined by 36.9% to $7.86 during Friday's regular session. The company's market cap stands at $25.4 million. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock fell 36.76% to $23.21. The company's market cap stands at $17.1 billion. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares fell 33.66% to $0.6. The company's market cap stands at $9.0 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock declined by 23.75% to $1.43. The company's market cap stands at $21.1 million. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock decreased by 21.4% to $1.02. The company's market cap stands at $85.6 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) stock declined by 21.1% to $15.47. The market value of their outstanding shares is at $101.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COEP

CYCC

INTS

NDRA

RBOT

SMMT

STRO

SXTC

VYNE

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock moved upwards by 37.6% to $1.1 during Thursday's regular session. The company's market cap stands at $5.9 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares increased by 26.43% to $0.4. The market value of their outstanding shares is at $9.2 million. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares increased by 24.8% to $9.76. The market value of their outstanding shares is at $462.5 million. </li>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares increased by 24.69% to $3.03. The market value of their outstanding shares is at $420.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 23.43% to $0.79. The market value of their outstanding shares is at $19.1 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 19.94% to $8.0. The market value of their outstanding shares is at $5.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 26.3% to $0.66 during Thursday's regular session. The company's market cap stands at $3.9 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 23.85% to $0.99. The company's market cap stands at $15.0 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 16.08% to $3.08. The company's market cap stands at $5.0 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) stock fell 15.17% to $20.0. The company's market cap stands at $2.1 billion. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock declined by 12.5% to $0.28. The market value of their outstanding shares is at $2.2 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 11.41% to $0.87. The market value of their outstanding shares is at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

CERO

ENSC

MTSR

NCNA

PSTV

RNAZ

VTAK

ZYBT

12 Health Care Stocks Moving In Thursday's Intraday Session

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines">PRIME</a> program for novel medicines targeting unmet medical needs and the FDA's <a href="https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/fact-sheet-breakthrough-therapies">Breakthrough Therapies</a> program
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 17, 2025 / <a href="https://pr.report/8vx8">Jaguar Health, Inc.</a> <a href="https://pr.report/8vx9">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/8vxa">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/8vxb">Napo Therapeutics</a> today announced that preliminary results from the ongoing pediatric investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders (CDD), including MVID and SBS with intestinal failure (SBS-IF), will be presented by Dr. Mohamad Miqdady at the April 24-26, 2025 <a href="https://pr.report/8vxc">Annual ELITE PED-GI Congress</a> in Abu Dhabi in the United Arab Emirates.
MVID and SBS-IF, rare orphan diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers. There are currently no approved drug treatments for MVID. A key value driver would be a reduction in total parenteral nutrition (TPN).
"Patients with MVID and SBS-IF suffer from devastating diarrhea and dehydration caused by these debilitating, lifelong conditions. These patients are frequently on TPN for as long as 20 hours a day, seven days a week - and TPN carries a significant risk of morbidity, including infections, metabolic complications, and liver problems," said Dr. Miqdady, the principal investigator for this study. "I look forward to presenting preliminary, proof-of-concept results from this study at the ELITE PED-GI Congress."
This ongoing proof-of-concept study is evaluating crofelemer's potential to be safely administered to patients with MVID, SBS-IF, and other CDDs in escalating doses, improve stool formation, improve the absorption of nutrients, and lower TPN needs - which have never been achieved in an MVID patient. The study also provides the opportunity to evaluate whether any potential benefit provided by crofelemer in participating patients ceases after treatment with crofelemer is discontinued.

Jaguar Health Announces Preliminary Results From Ongoing Pediatric Investigator-Initiated Trial Of A Novel Liquid Formulation Of Crofelemer Will Be Presented By Dr. Mohamad Miqdady At April 24-26, 2025 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates

The statistically significant responder analysis results for Mytesi&#xAE; (crofelemer) in the Phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the <a href="https://sabcs.org/Symposium-Overview-2024">San Antonio Breast Cancer Symposium</a>
Late-breaker abstract accepted by <a href="https://mascc.org/annualmeeting2025/">MASCC</a> shows additional significant results for breast cancer subgroup
Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer
A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 15, 2025 / <a href="https://pr.report/9ein">Jaguar Health, Inc.</a> <a href="https://pr.report/9eio">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or the "Company") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for presentation as an oral rapid e-poster at MASCC's June 26-28, <a href="https://pr.report/9eip">2025 Annual Meeting</a> in Seattle, Washington. The authors include Pravin Chaturvedi, PhD, who is Jaguar's Chief Scientific Officer and Chair of Napo's Scientific Advisory Board, as well as leading oncologists and cancer patient advocates.
The abstract is titled OnTarget: Crofelemer or Placebo for the Prophylaxis of Diarrhea in Adults with Solid Tumors Initiating Targeted Therapy ± Chemotherapy (Tt/C)
"We're very pleased about the acceptance by MASCC of this new abstract, which describes the proportion of breast cancer patients who were continuous responders for the entire 3-month period of the OnTarget trial compared to breast cancer patients in the placebo arm of the study," said Lisa Conte, Jaguar's president and CEO.
"As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe the published results of crofelemer for the prophylaxis of cancer therapy-related are very exciting and compelling," said Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who serves on Napo's Scientific Advisory Board (SAB).
As announced, the U.S. Food and Drug Administration (FDA) has granted Napo a Type C Meeting in the second quarter of 2025 to discuss the responder analysis in the prespecified subgroup of patients with breast cancer for crofelemer in Napo's Phase 3 OnTarget trial. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy. The American Cancer Society expects 316,950 new cases of breast cancer diagnosed in women in the US in 2025,1 and it's estimated that there were 4 million US women with a history of invasive breast cancer in 2022.2
"Diarrhea is a common side effect of targeted cancer therapies and can lead to dose changes, treatment delays, or cessation of treatment altogether, all of which can impact patient outcomes. We are very happy to have been granted a meeting with the FDA to review the positive OnTarget results in breast cancer patients and our goal is to discuss the most efficient pathways to make crofelemer - our novel, oral plant-based prescription medicine - available to this patient population for cancer therapy-related diarrhea (CTD)," said Conte.
Members of Napo's SAB are expected to join Jaguar representatives at the FDA meeting in the second quarter of 2025.
As previously announced, the initial top line results from the OnTarget study showed that the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types. The subgroup analysis in adult breast cancer patients indicates that crofelemer achieved significant results in this subgroup.
Napo today also announced that a second late-breaker abstract, related to the results of a recent Napo-sponsored screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting. The abstract is titled Beyond the Pain: Patient Insights on Oral Mucositis in Cancer Treatment.
"Oral mucositis is a common, painful, and life-altering side effect of cancer treatment, frequently disrupting eating, speaking, sleeping, and social interactions. Capturing real-world patient experiences and insights can help to identify patient priorities and co-create solutions to support prevention and management of oral mucositis and enhance quality of life," said Stacey Tinianov, 11-year cancer survivor and founder of <a href="https://pr.report/9eiq">Advocates for Collaborative Education</a> who serves on Napo's SAB. "I am delighted and honored that the results of the screening survey and focus group will be presented at MASCC's Annual Meeting this June."
Ms. Tinianov coordinated the screening survey and focus group in conjunction with cancer patients who serve as Ambassadors for Napo's ongoing <a href="https://pr.report/9eir">Make Cancer Less Shitty</a> (MCLS) patient advocacy program. The goal of the MCLS program is to drive awareness of cancer supportive care gaps and needs, bring together patients, advocates, researchers, and clinicians, and, most importantly, to amplify the voice of patients about the importance of supportive care.
"Oral mucositis has impacted my daily life constantly since 2016. Without proper supportive care, I have raw mouth sores and ulcerations from my gums and lips all the way down my throat. When severe, it impacts what I am able to eat, how I'm able to eat, and sometimes my ability to talk. The pain and irritation from oral mucositis affects my sleep and my self-confidence," said JJ Singleton, a metastatic colon cancer survivor and an Ambassador for Napo's MCLS patient advocacy program.
<a href="https://pr.report/9eis">MASCC</a> is an international, interdisciplinary organization dedicated to the practice, education and research of supportive care in cancer. The organization's mission is to continually improve the supportive care of people with cancer - from diagnosis through to survival or end-of-life care.

Jaguar Health Says Late-Breaker Abstract On Addl Results In Adult Breast Cancer Patients From OnTarget Study Accepted For Presentation As Oral Rapid E-poster At MASCC Annual Meeting

Jaguar Health, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three other members of the Company's board of directors, and seven other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase agreements, pursuant to which the Company will issue up to $3.448 million aggregate principal amount of convertible promissory notes (collectively, the "Notes") to such Investors in a private placement priced at-the-market under Nasdaq rules. The Notes will have a 3-month maturity, will bear interest at 6% per annum, and will be convertible immediately at the option of the Investors into shares of the Company's common stock.

Jaguar Health Announces $3.448M Private Placement Of Convertible Promissory Notes With CEO, Board Members, And Senior Executives Participating; Notes Have A 3-Month Maturity, 6% Interest, Will Be Convertable Immediately Into Common Stock

<h3>Gainers</h3>
<ul>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares increased by 49.0% to $0.13 during Tuesday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 24.37% to $23.01. The company's market cap stands at $299.4 million. </li>
<li>Opus Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRD#NASDAQ">IRD</a>) shares increased by 20.0% to $1.13. The market value of their outstanding shares is at $35.6 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) shares moved upwards by 19.85% to $2.9. The market value of their outstanding shares is at $122.6 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock increased by 19.12% to $1.58. The market value of their outstanding shares is at $30.5 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock rose 18.67% to $19.32. The market value of their outstanding shares is at $108.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 47.2% to $0.45 during Tuesday's regular session. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock decreased by 40.6% to $0.28. The company's market cap stands at $4.5 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares declined by 27.76% to $0.92. The company's market cap stands at $71.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) stock fell 26.51% to $9.03. The company's market cap stands at $774.5 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares fell 23.2% to $0.13. The market value of their outstanding shares is at $2.3 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares declined by 20.82% to $80.25. The company's market cap stands at $7.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXI

GYRE

HURA

HYPR

OSRH

SRPT

SYRS

TNXP

VRPX

12 Health Care Stocks Moving In Tuesday's Intraday Session

WIIM

Jaguar Health shares are trading lower after the company announced a 1-for-25 reverse stock split.

Jaguar Health Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares are trading lower by 40.1% to 28 cents during Tuesday&#8217;s session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/03/ac44375204/jaguar-health-inc-announces-reverse-stock-split">1-for-25 reverse stock split</a> of its common stock, set to take effect on March 24, to maintain compliance with Nasdaq listing requirements.
The stock will trade on a split-adjusted basis under the same ticker. CEO Lisa Conte stated the move aims to attract institutional investors by adjusting the share price and count. 
Approved by stockholders at a Special Meeting, the split will convert every 25 shares into one without changing par value. 
No fractional shares will be issued, and stockholders will receive cash for fractions. Equiniti Trust Company, LLC will manage the exchange, with brokerage account holders requiring no action.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/03/44378861/stock-of-the-day-does-classic-pattern-in-microsoft-mean-a-move-higher">Stock Of The Day – Does Classic Pattern In Microsoft Mean A Move Higher?</a>
<h2 class="wp-block-heading">Is JAGX A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/JAGX">Jaguar Health</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/JAGX">Jaguar Health</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, JAGX has a 52-week high of $21.60 and a 52-week low of $0.32.

Why Jaguar Health (JAGX) Stock Is Trading Lower

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease
FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> trial of crofelemer in the prespecified subgroup of patients with breast cancer
Jaguar has received an indication of interest to acquire the Company
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / February 27, 2025 / <a href="https://pr.report/7peo">Jaguar Health, Inc.</a> <a href="https://pr.report/7pep">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar" or the "Company") today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights plan (the "Rights Plan").

Contracts

Management

Jaguar Health Adopts Limited Duration Stockholder Rights Plan To Ensure Stockholders Can Realize Long-Term Value; Jaguar Has Received An Indication Of Interest To Acquire The Company

Jaguar Health Announces Phase 2 Study Of Crofelemer For SBS-IF In Adults Cleared In Italy And Germany; Trial Initiated February 18, 2025

Jaguar Health Extends Collaboration With Streeterville For Possible Tropical Disease Priority Review Voucher And Cholera Indication For NP-300

Trial taking place at <a href="https://www.seha.ae/hospital-detail/1">Sheikh Khalifa Medical City</a>, a flagship tertiary hospital in the United Arab Emirates
POC data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for MVID
Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome with intestinal failure (SBS-IF)
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / January 22, 2025 / <a href="https://pr.report/66fk">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/66fm">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/66fn">Napo Therapeutics</a> today announced that the first patient has been dosed in the independent investigator-initiated POC trial of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of MVID in pediatric patients. POC data generated from this study potentially in the first half of 2025 could lead to reimbursed early patient access to crofelemer for this indication in certain European countries.
The trial will also include pediatric patients with SBS-IF. It is being conducted by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology who is the Division Chief of the Pediatric Gastroenterology, Hepatology &amp; Nutrition Division at <a href="https://pr.report/66fo">Sheikh Khalifa Medical City</a> (SKMC), a flagship tertiary hospital in the UAE and the largest teaching medical center in Abu Dhabi.

Jaguar Health Announces First Patient Dosed In UAE POC Trial For Crofelemer In Pediatric MVID; Potential For Early Access In Europe By H1 2025; Drug Holds Orphan Designation For MVID And SBS-IF By FDA And EMA

Jaguar Health's  Napo Pharmaceuticals Announces FDA Orphan Drug Designation For Crofelemer

Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> trial evaluating crofelemer for prophylaxis of CTD
The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination
SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / <a href="https://pr.report/4u8b">Jaguar Health, Inc.</a> <a href="https://pr.report/4yse">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) ("Jaguar") family company <a href="https://pr.report/4u8d">Napo Pharmaceuticals</a> ("Napo") today provided an overview of the data from the poster presentation conducted yesterday, December 11, 2024, at the <a href="https://pr.report/4u8e">San Antonio Breast Cancer Symposium</a> (SABCS) about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 <a href="https://pr.report/4u8f">OnTarget</a> trial, which indicates that crofelemer achieved statistically significant results in this subgroup. Patients with breast cancer accounted for 183 of the 287 participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adults with solid tumors receiving targeted therapy with or without standard chemotherapy.

Jaguar Health's Napo Pharmaceuticals Reports Crofelemer Shows Statistically Significant Results In Phase 3 OnTarget Trial For Breast Cancer Patients

U.S. Investigator-Initiated Trial To Evaluate Efficacy And Safety Of Jaguar Health's Crofelemer For Short Bowel Syndrome With Intestinal Failure Begins

<a href="https://www.canalevia.com/">Canalevia&#xAE;-CA1</a> is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree
Crofelemer, the active ingredient in Canalevia CA-1, is the subject of Jaguar's recently conducted Phase 3 <a href="https://clinicaltrials.gov/study/NCT04538625">OnTarget</a> trial in humans for cancer therapy-related diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / December 5, 2024 / <a href="https://pr.report/4r5r">Jaguar Health, Inc.</a><a href="https://pr.report/4r6c">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) today announced that an article about <a href="https://pr.report/4r5s">Canalevia-CA1</a> (crofelemer delayed-release tablets), Jaguar's prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, has been published in PetVet Magazine and can be viewed by clicking <a href="https://pr.report/4r5t">here</a>.
Canalevia-CA1 is conditionally approved by the U.S. Food and Drug Administration for the treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any approval from the FDA.

Jaguar Health AnnouncesThat An Article About Canalevia-CA1 (Crofelemer Delayed-Release Tablets), Jaguar's Prescription Drug For The Treatment Of Chemotherapy-Induced Diarrhea In Dogs, Has Been Published In PetVet Magazine

Press Releases

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Comments

Jaguar Health

Vendite allo scoperto

Jaguar Health (NASDAQ:JAGX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO